Structural Formula (Cymbalta 01)
Cymbalta
Product Images NDC 68151-4734
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Cymbalta (NDC 68151-4734). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 3 (Cymbalta 02)
Figure 4 (Cymbalta 03)
Figure 5 (Cymbalta 13)
Figure 6 (Cymbalta 14)
Figure 7 (Cymbalta 15)
The text describes a chart or graph that shows the percentage of improvement in pain from baseline in patients who received a placebo and those who received CYM60/120 mg once a day. The percentages range from 0% to 100%, with the highest percentage of improvement at 100% in the group receiving CYM60/120 mg once a day. The chart also shows different levels of percentage improvement in pain from baseline at different points on the graph.*
Figure 8 (Cymbalta 16)
This appears to be a chart comparing the percentage of patients who have improved from baseline pain scores when taking either a placebo or CYMB0 mg once daily. The chart shows that 100% of patients improved when taking the CYMB0 mg once daily medication, represented by a solid line. The dotted line represents the improvement percentage for patients taking a placebo. The x-axis of the chart shows the levels of improvement in increments of 10%, and the y-axis represents the percentage of patients who have achieved that level of improvement.*
Figure 9 (Cymbalta 17)
This text describes a graph or chart showing the percentage of patients who improved while taking a placebo versus CYM60/120 mg once daily. The chart also includes percentage improvement in pain from baseline.*
Figure 1 (Cymbalta 18)
The graph shows the proportion of patients with relapse over time (in days) after randomization for a treatment group (CYMBALTA) and a placebo group. The X-axis represents the number of days, ranging from 0 to 250, and the Y-axis represents the proportion of patients with relapse, ranging from 0 to 1. The CYMBALTA treatment group has a lower proportion of patients with relapse compared to the placebo group.*
Figure 2 (Cymbalta 19)
Label Image (Lbl681514734)
This is a medication description for Cymbalta (generic name: Duloxetine) which is a 20mg delayed-release capsule produced by Lilly. The expiration date of the medication is 07/14 and the manufacturer's lot number is W010414SN20. It is a prescription-only drug with the code PDM: 4734.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
